The ADAP Advocacy Association (aaa+®) issued the following press releases:
How to Spot Fake HIV Medicines
WASHINGTON, D.C. (December 1, 2022) - The ADAP Advocacy Association (aaa+®) joins the Partnership for Safe Medicines (PSM) today to commemorate World AIDS Day 2022 by offering an important message for patients living with HIV/AIDS: protect yourselves against counterfeit medicines. With several high-profile incidents of fake HIV medicines entering the United States drug supply chain, World AIDS Day represents a unique opportunity to raise awareness about the real dangers facing patients living with HIV/AIDS. The message is designed to empower patients with important safety tips about medicine safety.
New Faces include Robert “Bobby” Dorsey, Esq. and Shabbir Imber Safdar
WASHINGTON, D.C. (November 29, 2022) - The ADAP Advocacy Association (aaa+®) today announced that it has seated two new members of its governing Board of Directors. Newly seated board members include Robert Dorsey, Esq. from Washington, DC, and Shabbir Imber Safdar from San Francisco, California. The new board members bring decades of their advocacy experience to the organization.
Appoints Ryan White Grantee 340B Patient Advisory Committee
WASHINGTON, D.C. (November 16, 2022) - The ADAP Advocacy Association (aaa+®) today launched its Ryan White Grantees 340B Project, which is designed to provide education, resources, and tools for patients seeking to participate in the national conversation about reforming the 340B Drug Discount Program. A focal point of the project will be a Ryan White Grantee 340B Patient Advisory Committee.
The Future is Now – Welcome to the Age of Injectables
WASHINGTON, D.C. (August 29, 2022) - The ADAP Advocacy Association (aaa+®) today shared its new comprehensive patient advocacy report, HIV LONG-ACTING AGENTS: Policy Considerations for Injectable Therapies under the Ryan White HIV/AIDS Program & State AIDS Drug Assistance Programs. This document provides a checklist of the main concepts requiring robust policy and programmatic conversations with people living with HIV/AIDS, as well as all the other local stakeholders within the local service delivery system regarding injectables.
Nearly 100 organizations endorse sign-on letter expressing concerns over S.4395
WASHINGTON, D.C. (August 15, 2022) - The ADAP Advocacy Association (aaa+®) today submitted a sign-on letter to Congress expressing the HIV Community’s collective concerns over the Ryan White PrEP Availability Act (S.4395). The sign-on letter – which was endorsed by nearly 100 national, state, and local organizations – is part of a national campaign to protect the Ryan White HIV/AIDS Program (RWHAP), namely opposing efforts to raid the program to fund pre-exposure prophylaxis.
Announcement made during U=U Global Summit in Montreal
WASHINGTON, D.C. (August 1, 2022) - The ADAP Advocacy Association (aaa+®) today applauded the governments of the United States and Canada for formally supporting the science behind and messaging for Undetectable = Untransmittable (U=U). U=U fortifies that people living with HIV who are taking their medication and have an undetectable viral load can’t spread HIV sexually. The U=U Campaign, spearheaded by the Prevention Access Campaign (PAC), has been widely recognized as a transformative message, and now the U.S. and Canadian governments have joined the U=U chorus.
WASHINGTON, D.C. (July 19, 2022) - The Board of Directors for the ADAP Advocacy Association (aaa+®) and the Community Access National Network (CANN) issued the following joint statement in response to the news about Edward "Eddie" Hamilton’s passing on Tuesday, July 12th.
S.4395 would divert limited resources away from care to prevention
WASHINGTON, D.C. (July 13, 2022) - The ADAP Advocacy Association (aaa+®) today expressed strong opposition to raiding the Ryan White HIV/AIDS Program (RWHAP) to fund prevention programs, including access to pre-exposure prophylaxis. For over thirty years, RWHAP has served as the nation’s only public health program solely dedicated to providing support and services to people living with HIV/AIDS (PLWHA). Instead, other programs that already exist for prevention services should be strengthened and better funded.
Highlighting its Commitment to Access, Information & Participation
WASHINGTON, D.C. (May 3, 2022) - The ADAP Advocacy Association (aaa+®) today released its 2021 Annual Report – which highlights the organization’s ongoing commitment to access, information and participation for patient advocacy designed to promote and protect the AIDS Drug Assistance Program (“ADAP”). The report is shared using an infographic format to capture the previous year’s highlights.
Highlights important steps patients living with HIV/AIDS can take to protect themselves against counterfeit HIV medicines
WASHINGTON, D.C. (March 14, 2022) - The ADAP Advocacy Association (aaa+®) today aired its Public Service Announcement designed to raise awareness about the dangers of counterfeit drugs. The PSA comes in response to Gilead Sciences recently warning patients living with HIV/AIDS about counterfeit HIV medication being distributed in the United States.
Retreats designed to assemble key stakeholder groups to discuss pertinent issues facing people living with HIV/AIDS
WASHINGTON, D.C. (February 10, 2022) - The ADAP Advocacy Association (aaa+®) today announced it would resume its face-to-face advocacy starting later this year, after a two-year pause in response to the Covid-19 pandemic.